← Back to Clinical Trials
Recruiting NCT06017713

tDCS Associated With Symptom Provocation in the Management of Patients With Resistant Obsessive Compulsive Disorder

Trial Parameters

Condition Obsessive-Compulsive Disorder
Sponsor Centre Hospitalier Henri Laborit
Study Type INTERVENTIONAL
Phase N/A
Enrollment 25
Sex ALL
Min Age 18 Years
Max Age 70 Years
Start Date 2023-10-17
Completion 2027-04
Interventions
tDCS + symptoms provocation

Brief Summary

This is a single-center study about patients with severe resistant OCD. Main assumption is that performing 10 tDCS sessions with the anode positioned at the level of the right orbitofrontal cortex, and the cathode at the level of the supplementary motor area, associated with the provocation of symptoms before each session is effective in the reduction in obsessive-compulsive symptoms. After the inclusion visit, the treatment period is provided from D1 to D12 (one session per day from Monday to Friday, for two consecutive weeks, i.e. a total of ten sessions). Each tDCS session lasts 30 minutes at an intensity of 2 mA and is preceded by symptom provocation using a standardized procedure performed by trained personnel. The patients are then assessed on D42 and D102 (i.e. 1 month and 3 months after the end of the tDCS sessions).

Eligibility Criteria

Inclusion Criteria: * Patient suffering from OCD evolving for at least 2 years diagnosed according to DSM-V criteria; * Patient with good insight, defined by a score less than or equal to 18 at the threshold of delusions on the BABS (Brown Assessment of Beliefs Scale) insight scale; * Absence of a current depressive episode (MADRS score \< 21) or suicidal risk (MADRS score item 10 \< 3); * Absence of epileptic pathology; * Chronic obsessive-compulsive disorder defined by a total YBOCS score \> 20, or a subscale score \> 15; * Drug-resistant obsessive-compulsive disorder despite treatment with: 1. at least 2 antidepressants of the IRS type at an effective dose and for a sufficient duration 2. and/or Behavioral and Cognitive therapy for at least 1 year; * Therapeutic stability (antidepressants) for more than 12 weeks without significant improvement. This treatment, at a fixed dose, will be maintained during the study; * Patient aged between 18 and 70 included * Patient who has given his/

Related Trials